triple

By Targets:	5-HT Receptor (2) ADC Antibody (1) Adrenergic Receptor (1) Akt (2) Aminoacyl-tRNA Synthetase (2) Amyloid-β (1) Antibiotic (1) Apoptosis (39) Aryl Hydrocarbon Receptor (1) Aurora Kinase (2) Autophagy (10) Bacterial (2) Bcl-2 Family (3) Beta-secretase (2) Casein Kinase (2) Caspase (1) CDK (9) Cholinesterase (ChE) (3) CXCR (1) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (4) Dopamine Receptor (1) Dopamine Transporter (4) DYRK (2) EGFR (6) Endogenous Metabolite (4) Epigenetic Reader Domain (5) FAK (1) Ferroptosis (3) FGFR (6) FLT3 (1) Fungal (1) GCGR (3) GLP Receptor (3) Glutaminase (1) Glutathione Peroxidase (2) GSK-3 (2) HDAC (5) Histone Methyltransferase (7) HIV (1) HSP (3) Influenza Virus (1) Isotope-Labeled Compounds (3) JAK (1) Ligands for E3 Ligase (1) MDM-2/p53 (2) MicroRNA (2) mTOR (2) Neurokinin Receptor (1) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) PAI-1 (1) PAK (1) PARP (6) PD-1/PD-L1 (1) PDGFR (5) Phosphatase (3) PI3K (2) PROTAC Linkers (1) PROTACs (5) Pyruvate Kinase (1) Ras (1) SARS-CoV (1) Ser/Thr Protease (1) Serotonin Transporter (4) SHP2 (1) Sirtuin (3) STAT (2) Tau Protein (1) ULK (4) VEGFR (5) Wnt (1)
By Research Areas:	Cancer (100) Cardiovascular Disease (1) Endocrinology (2) Infection (6) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (9)
Click Chemistry:	Alkynes (5)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131067

EMI56

EGFR Cancer

EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants .

EMI56	EGFR	Cancer
EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants .

HY-101923B

LYN-1604 dihydrochloride 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923

LYN-1604

ULK Autophagy Apoptosis Cancer

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

LYN-1604	ULK Autophagy Apoptosis	Cancer
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923A

LYN-1604 hydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-157210

CDK7-IN-26	CDK	Cancer
CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC₅₀: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC₅₀ of 0.15 μM .

HY-124817

Col003 2 Publications Verification	HSP	Inflammation/Immunology
Col003 is a selective and potent inhibitor of Hsp47 and competitively binds to the collagen binding site on Hsp47 (IC₅₀=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix. Col003 can be used for the investigation of fibrosis

HY-131339

SP-96	Aurora Kinase	Cancer
SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .

HY-14472

Tesofensine NS-2330	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR ^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1 .

HY-103157

PD146176 2 Publications Verification NSC168807	Autophagy Ferroptosis	Cardiovascular Disease
PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (K_i=197 nM, IC₅₀=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

HY-147373

DA-PROTAC	PROTACs Ligands for E3 Ligase	Cancer
DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research .

HY-139632

Ascochlorin A Acremochlorin A	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
Ascochlorin A is a novel and potent hDHODH inhibitor (K_D = 3.29 μM) for research of triple-negative breast cancer.

HY-114979

Pyoluteorin	Antibiotic Fungal Apoptosis	Infection Cancer
Pyoluteorin is an antibiotic that inhibits Oomycete fungi, including the plant pathogen Pythium ultimum, and suppresses plant diseases caused by this fungus . Pyoluteorin induces human triple-negative breast cancer MDA-MB-231 cells apoptosis in vitro. Pyoluteorin can be used for the research of human triple-negative breast cancer .

HY-12015

Iniparib 5+ Cited Publications BSI-201; NSC-746045; IND-71677	PARP Influenza Virus	Cancer
Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

HY-12850

Dasotraline SEP 225289	Dopamine Transporter Serotonin Transporter	Neurological Disease
Dasotraline is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC₅₀ values of 4, 6, and 11 nM, respectively.

HY-142908

Maximiscin	Endogenous Metabolite	Cancer
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-139832

MCX 28

PI3K mTOR Cancer

MCX 28, a triple PI3K/mTOR/PIM inhibitor, displays low nanomolar activity.

MCX 28	PI3K mTOR	Cancer
MCX 28, a triple PI3K/mTOR/PIM inhibitor, displays low nanomolar activity.

HY-12850A

Dasotraline hydrochloride SEP-225289 hydrochloride	Serotonin Transporter Dopamine Transporter	Neurological Disease
Dasotraline hydrochloride (SEP-225289 hydrochloride) is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC₅₀ values of 4, 6, and 11 nM, respectively.

HY-139742

ADTL-SA1215

Sirtuin Cancer

ADTL-SA1215 is a first-in-class specific small-molecule activator of SIRT3 that modulates autophagy in triple negative breast cancer.

ADTL-SA1215	Sirtuin	Cancer
ADTL-SA1215 is a first-in-class specific small-molecule activator of SIRT3 that modulates autophagy in triple negative breast cancer.

HY-U00096

Ansofaxine hydrochloride LY03005; LPM570065	5-HT Receptor Dopamine Receptor	Neurological Disease Inflammation/Immunology
Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits serotonin, dopamine and norepinephrine reuptake with IC₅₀ values of 723, 491 and 763 nM, respectively.

HY-125465

SLLN-15	Autophagy	Cancer
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) .

HY-132883

EGFR/CSC-IN-1

EGFR Cancer

EGFR/CSC-IN-1 is a potential EGFR (IC₅₀ 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer research.
HY-139830

Dyrk1A-IN-1

DYRK Neurological Disease

Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC₅₀ = 119 nM) and the aggregation of tau and α-syn oligomers.
HY-131066

EMI48

EGFR Cancer

EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants .
HY-163381

Antiproliferative agent-48

Others Cancer

Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .
HY-119653

AZ9482

PARP Cancer

AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

EGFR/CSC-IN-1	EGFR	Cancer
EGFR/CSC-IN-1 is a potential EGFR (IC₅₀ 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer research.

Dyrk1A-IN-1	DYRK	Neurological Disease
Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC₅₀ = 119 nM) and the aggregation of tau and α-syn oligomers.

EMI48	EGFR	Cancer
EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants .

Antiproliferative agent-48	Others	Cancer
Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .

AZ9482	PARP	Cancer
AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-152536

iNOS inhibitor-10	NO Synthase	Cancer
iNOS inhibitor-10 is an iNOS inhibitor (IC₅₀: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells .

HY-19634

YK-3-237

Sirtuin Cancer

YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells .

YK-3-237	Sirtuin	Cancer
YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells .

HY-150757

Autophagy-IN-2	Autophagy Apoptosis	Cancer
Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research .

HY-P5297

DOTA-CXCR4-L

CXCR Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

DOTA-CXCR4-L	CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-132885

PARP/EZH2-IN-1	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC₅₀ 6.87 nM) and EZH2 (IC₅₀ 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

HY-P99045

Sacituzumab	ADC Antibody	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research .

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-N0770

Isoliensinine	Apoptosis	Inflammation/Immunology Cancer
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-156698

HJM-561	PROTACs	Inflammation/Immunology
HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC. HJM-561 overcomes osimertinib (HY-15772)-resistant EGFR triple mutations and has anti-tumor activity .

HY-149847

JH530	Others	Cancer
JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits MDM2-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-N6007

Chrysosplenol D	Apoptosis	Infection Inflammation/Immunology Cancer
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities .

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .

HY-146264

Antibacterial agent 91	Aminoacyl-tRNA Synthetase Bacterial	Infection
Antibacterial agent 91 (Compound 36b) is a triple-site aminoacyl-tRNA synthetase (aaRS) inhibitor with an IC₅₀ of 2.10 μM against Salmonella enterica threonyl-tRNA synthetase (SeThrRS). Antibacterial agent 91 exhibits antibacterial activities .

HY-146265

Antibacterial agent 92	Aminoacyl-tRNA Synthetase Bacterial	Infection
Antibacterial agent 92 (Compound 36k) is a triple-site aminoacyl-tRNA synthetase (aaRS) inhibitor with an IC₅₀ of 0.58 μM against Salmonella enterica threonyl-tRNA synthetase (SeThrRS). Antibacterial agent 92 exhibits antibacterial activities .

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	STAT	Cancer
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-138072

EMI1	EGFR	Cancer
EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) .

HY-155251

anti-TNBC agent-3	Apoptosis Bcl-2 Family	Cancer
anti-TNBC agent-3 (compound 3g) is an apoptosis inducer with anti-cancer cell proliferation activity. anti-TNBC agent-3 inhibits tumor growth and metastasis in triple-negative breast cancer (TNBC) xenograft models .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-156700

Lenalidomide-acetylene-Br	PROTAC Linkers	Cancer
Lenalidomide-acetylene-Br is a PROTAC Linker taht makes up HJM-561 (HY-156698). HJM-561 is a potent, selective, and orally active EGFR PROTAC to inhiibit Osimertinib (HY-15772)-resistant EGFR triple mutations.

HY-101567

BMS-986158 2 Publications Verification	Epigenetic Reader Domain	Cancer
BMS-986158 is a potent BET inhibitor with IC₅₀s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively .

HY-155490

Nur77 antagonist 1	Nuclear Hormone Receptor 4A/NR4A Apoptosis	Cancer
Nur77 antagonist 1(Compound ja) is a selective Nur77 antagonist(K_D ^SPR_Nur77 = 91 nM). Nur77 antagonist 1 induces cancer cell apoptosis. ja displays excellent antitumor against triple-negative breast cancer (TNBC) cells .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

1953 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1953 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area

HY-P3506

Retatrutide LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506A

Retatrutide TFA LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P5297

DOTA-CXCR4-L

CXCR Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

Cat. No.	Product Name	Target	Research Area

HY-P99045

Sacituzumab	ADC Antibody	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0770

Isoliensinine	Alkaloids Structural Classification Monophenols Classification of Application Fields Source classification Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Nymphaeaceae	Apoptosis
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-N6007

Chrysosplenol D	Infection Flavonols Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology	Apoptosis
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities .

HY-N0587

Demethylzeylasteral 2 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Source classification Celastraceae Plants Tripterygium wilfordii Hook. f. Inflammation/Immunology Disease Research Fields	Apoptosis
Demethylzeylasteral is a triterpene compound isolated from Tripterygium wilfordii Hook F, with anti-inflammatory, immunosuppressive and anti-tumor activities . Demethylzeylasteral can significantly alleviates atherosclerosis (AS) . Demethylzeylasteral inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways .

HY-142908

Maximiscin	Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	Structural Classification Terpenoids Sesquiterpenes Source classification Plants Compositae Guilandina minax (Hance) G. P. Lewis	STAT
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-N0331

Ziyuglycoside I	Triterpenes Structural Classification Classification of Application Fields Sanguisorba officinalis Linn. Terpenoids Source classification Rosaceae Plants Disease Research Fields Cancer	MDM-2/p53 Apoptosis
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics . Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC) .

HY-40136

cis-4-Hydroxy-L-proline	Microorganisms Classification of Application Fields Santalum album Linn. Ketones, Aldehydes, Acids Source classification Metabolic Disease Plants Endogenous metabolite Disease Research Fields Santalaceae	Endogenous Metabolite
cis-4-Hydroxy-L-proline, a proline analogue, is an inhibitor of collagen production. cis-4-Hydroxy-L-proline could inhibit fibroblast growth by preventing the deposition of triple-helical collagen on the cell layer. cis-4-Hydroxy-L-proline also depresses the growth of primary N-nitrosomethylurea-induced rat mammary tumors .

HY-108692

Enterolactone	Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .

Species:	Human (1) Rat (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P70092

	CTHRC1 Protein, Human (HEK293, His) rHuCollagen triple helix repeat-containing protein 1/CTHRC1, His; Collagen triple helix repeat-containing protein 1; Protein NMTC1; CTHRC1	Human	HEK293
	CTHRC1 Protein, Human (HEK293, His) is a negative regulator of collagen matrix deposition. CTHRC1, a secreted 28-kDa protein, is a glycosylated protein with a signal sequence.

HY-P76299

	CTHRC1 Protein, Rat (HEK293, His) Collagen triple helix repeat-containing protein 1; Protein NMTC1; CTHRC1	Rat	HEK293
	CTHRC1, with predicted Wnt-protein and frizzled binding activity, influences cell migration. Located in the extracellular matrix, this protein, implicated in Barrett's esophagus, exhibits biased expression in lung (RPKM 46.1) and muscle (RPKM 36.6), suggesting its role in diverse physiological processes across tissues. CTHRC1 Protein, Rat (HEK293, His) is the recombinant rat-derived CTHRC1 protein, expressed by HEK293 , with C-His labeled tag. The total length of CTHRC1 Protein, Rat (HEK293, His) is 230 a.a., with molecular weight of ~27 KDa.

Cat. No.	Product Name	Chemical Structure

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-40136S

cis-4-Hydroxy-L-proline-d3

cis-4-Hydroxy-L-proline-d₃ is the deuterium labeled cis-4-Hydroxy-L-proline. cis-4-Hydroxy-L-proline, a proline analogue, is an inhibitor of collagen production. cis-4-Hydroxy-L-proline could inhibit fibroblast growth by preventing the deposition of triple-helical collagen on the cell layer. cis-4-Hydroxy-L-proline also depresses the growth of primary N-nitrosomethylurea-induced rat mammary tumors[1][2][3][4].

Cat. No.	Product Name		Classification

HY-135699

TD52 1 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 1 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-132913

Cyclopropenone probe 1		Alkynes
Cyclopropenone probe 1 can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1), by covalently binding at the catalytic active site. Cyclopropenone probe 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

HY-145749

PARPYnD		Alkynes
PARPYnD is a PARP enzyme photoaffinity probe (AfBP) based on the triple PARP1/2/6 inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry